Sign in Subscribe
Stock exchanges

Avadel Pharmaceuticals PLC Files Form 8-K Report with US SEC

Strategic Insights

— 2 min read

Avadel Pharmaceuticals PLC has filed a Form 8-K report with the United States Securities and Exchange Commission (SEC) on September 17, 2025, disclosing significant developments in a lawsuit involving LUMRYZ patent infringement. The report highlights a court ruling requiring Avadel CNS to pay an ongoing royalty of 3.85% on sales of LUMRYZ to Jazz Pharmaceuticals, Inc. The royalty payment will continue until the expiration of the U.S. Patent No. 11,147,782 on February 18, 2036. Avadel Pharmaceuticals PLC disagrees with the underlying jury decision and plans to contest it.

Key Takeaways:

  • Avadel Pharmaceuticals PLC filed a Form 8-K report on September 17, 2025, with the US SEC, disclosing a court ruling in a lawsuit involving patent infringement of LUMRYZ.
  • The court ruled that Avadel CNS must pay an ongoing royalty of 3.85% on sales of LUMRYZ to Jazz Pharmaceuticals, Inc., which will continue until the expiration of the U.S. Patent No. 11,147,782 on February 18, 2036.
  • Avadel Pharmaceuticals PLC disagrees with the underlying jury decision and plans to contest it, with the company set to continue accruing the royalty and recognizing liability on its balance sheet.
  • The company's forward-looking statements include plans to contest the jury decision regarding the validity of the '782 Patent and any related royalty obligation.
  • Avadel Pharmaceuticals PLC is subject to significant risks and uncertainties, including patent disputes and royalty obligations, which may impact its business and operations.
  • The company's forward-looking statements are based on estimates and assumptions that are made within the bounds of its knowledge of its business and operations.
  • Avadel Pharmaceuticals PLC has a strong commitment to contesting the jury decision and upholding the validity of the '782 Patent, with its General Counsel and Corporate Secretary, Jerad G. Seurer, signing the Form 8-K report on behalf of the company.

Statistics:

  • 3.85%: The ongoing royalty rate Avadel CNS must pay on sales of LUMRYZ to Jazz Pharmaceuticals, Inc.
  • February 18, 2036: The expiration date of the U.S. Patent No. 11,147,782, marking the end of the royalty payment obligation.
  • March 3, 2025: The date Avadel Pharmaceuticals PLC filed its Annual Report on Form 10-K with the SEC.
  • May 12, 2021: The date Jazz Pharmaceuticals, Inc. initiated a formal complaint against Avadel CNS in the United States District Court for the District of Delaware.
  • August 27, 2024: The date the Court issued an opinion and order granting Jazz's motion for an ongoing royalty on the sale of LUMRYZ.
  • September 15, 2025: The date the Court issued an opinion and order requiring Avadel CNS to pay a future ongoing royalty of 3.85% on sales of LUMRYZ.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. 20549
  • FORM 8-K CURRENT REPORT, Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
  • AVADEL PHARMACEUTICALS PLC, 10 Earlsfort Terrace Dublin 2, Ireland, D02 T380
  • AVADEL PHARMACEUTICALS PLC, General Counsel and Corporate Secretary, Jerad G. Seurer
  • United States District Court for the District of Delaware, May 12, 2021, Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

Read more